NASDAQ:THAR Tharimmune (THAR) Stock Price, News & Analysis $3.00 +0.10 (+3.45%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.85▼$3.0450-Day Range$2.68▼$4.2852-Week Range$2.54▼$142.50Volume19,805 shsAverage Volume38,193 shsMarket Capitalization$2.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Tharimmune alerts: Email Address Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Tharimmune Stock (NASDAQ:THAR)Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.Read More THAR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart THAR Stock News HeadlinesAugust 12, 2024 | investorplace.comTHAR Stock Earnings: Tharimmune Reported Results for Q2 2024May 29, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune to Present at 2024 BIO International ConventionSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.May 29, 2024 | finance.yahoo.comTharimmune to Present at 2024 BIO International ConventionMay 24, 2024 | investorplace.comWhy Is Tharimmune (THAR) Stock Moving Today?May 22, 2024 | msn.comWhy Tharimmune (THAR) Shares Are MovingMay 22, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune Announces 1-for-15 Reverse Stock SplitMay 22, 2024 | finance.yahoo.comTharimmune Announces 1-for-15 Reverse Stock SplitSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.May 9, 2024 | investorplace.comTHAR Stock Earnings: Tharimmune Reported Results for Q4 2023May 2, 2024 | finance.yahoo.comStonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus ManagementApril 24, 2024 | finance.yahoo.comTharimmune, Inc. (THAR)April 18, 2024 | morningstar.comTharimmune Inc THARApril 16, 2024 | investing.comTharimmune forms advisory board to guide drug developmentFebruary 21, 2024 | msn.comTharimmune’s buccal film liver drug demonstrates effectiveness in Phase I trialFebruary 20, 2024 | msn.comTharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver DiseaseFebruary 20, 2024 | finanznachrichten.deTharimmune, Inc.: Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic CandidateFebruary 20, 2024 | finance.yahoo.comTharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic CandidateSee More Headlines Receive THAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tharimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:THAR Previous SymbolNASDAQ:THAR CUSIPN/A CIK1861657 Webwww.hillstreambio.com Phone908-955-3140FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-144.13% Return on Assets-113.57% Debt Debt-to-Equity RatioN/A Current Ratio5.28 Quick Ratio5.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.83 per share Price / Book0.51Miscellaneous Outstanding Shares786,000Free Float767,000Market Cap$2.36 million OptionableNot Optionable Beta1.50 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Randy D. Milby MBA (Age 70)President, Chairman & CEO Comp: $593.75kMr. Sireesh Appajosyula Pharm.D. (Age 48)COO & Director Comp: $584.8kMr. Thomas P. Hess CPA (Age 60)MBA, Chief Financial Officer Key CompetitorsEterna TherapeuticsNASDAQ:ERNAViracta TherapeuticsNASDAQ:VIRXConduit PharmaceuticalsNASDAQ:CDTVaccinexNASDAQ:VCNXMonopar TherapeuticsNASDAQ:MNPRView All CompetitorsInsidersRandy MilbyBought 1,933 shares on 12/15/2023Total: $14,497.50 ($7.50/share)Randy MilbyBought 666 shares on 11/30/2023Total: $9,990.00 ($15.00/share)View All Insider Transactions THAR Stock Analysis - Frequently Asked Questions How have THAR shares performed this year? Tharimmune's stock was trading at $7.6350 on January 1st, 2024. Since then, THAR shares have decreased by 60.7% and is now trading at $3.00. View the best growth stocks for 2024 here. How were Tharimmune's earnings last quarter? Tharimmune, Inc. (NASDAQ:THAR) released its earnings results on Friday, August, 9th. The company reported ($2.42) earnings per share for the quarter. When did Tharimmune's stock split? Tharimmune shares reverse split before market open on Tuesday, May 28th 2024. The 1-15 reverse split was announced on Tuesday, May 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Tharimmune? Shares of THAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:THAR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.